 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Elizabeth Blair and Zhen Gooi.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.773 |
|
|
|
-
Yesensky J, Agrawal N, Bayan S, Blair E, Portugal L, Chan J, Goldenberg D, Gooi Z. AHNS Series - Do you know your guidelines? Principles of treatment for glottic cancer: A review of the National Comprehensive Cancer Network guidelines. Head Neck. 2017 09; 39(9):1729-1732.
Score: 0.177
-
Gooi Z, Richmon J, Agrawal N, Blair E, Portugal L, Vokes E, Seiwert T, de Souza J, Saloura V, Haraf D, Goldenberg D, Chan J. AHNS Series - Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines. Head Neck. 2017 02; 39(2):201-205.
Score: 0.170
-
Rosenberg AJ, Izumchenko E, Pearson A, Gooi Z, Blair E, Karrison T, Juloori A, Ginat D, Cipriani N, Lingen M, Sloane H, Edelstein DL, Keyser K, Fredebohm J, Holtrup F, Jones FS, Haraf D, Agrawal N, Vokes EE. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
Score: 0.060
-
Hara J, Rosenberg AJ, Pearson A, Gooi Z, Baird BJ, Blair EA, Agrawal N, Vokes EE, Haraf DJ, Juloori A. Organ Preservation With Definitive Chemoradiotherapy for T4 Laryngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e363.
Score: 0.060
-
Rosenberg AJ, Agrawal N, Pearson A, Gooi Z, Blair E, Cursio J, Juloori A, Ginat D, Howard A, Chin J, Kochanny S, Foster C, Cipriani N, Lingen M, Izumchenko E, Seiwert TY, Haraf D, Vokes EE. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
Score: 0.060
-
Foster CC, Seiwert TY, MacCracken E, Blair EA, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Gooi Z, Spiotto MT, Vokes EE, Haraf DJ. Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes. Int J Radiat Oncol Biol Phys. 2020 07 15; 107(4):662-671.
Score: 0.054
-
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 10 01; 30(10):1673.
Score: 0.052
-
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
Score: 0.049
-
Foster CC, Melotek JM, Brisson RJ, Seiwert TY, Cohen EEW, Stenson KM, Blair EA, Portugal L, Gooi Z, Agrawal N, Vokes EE, Haraf DJ. Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol. 2018 05; 80:16-22.
Score: 0.046
-
Yesensky JA, Hasina R, Wroblewski KE, Bellairs J, Gooi Z, Saloura V, Cipriani NA, Vokes EE, Portugal LG, Seiwert TY, Blair ED, Agrawal N. Role of dental hardware in oral cavity squamous cell carcinoma in the low-risk nonsmoker nondrinker population. Head Neck. 2018 04; 40(4):784-792.
Score: 0.046
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|